Targeting neural reflex circuits in immunity to treat kidney disease

被引:61
|
作者
Okusa, Mark D. [1 ]
Rosin, Diane L. [2 ]
Tracey, Kevin J. [3 ,4 ]
机构
[1] Ctr Immun Inflammat & Regenerat Med, Div Nephrol, POB 800133,1300 Jefferson Pk Ave Wes Complex, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Pharmacol, POB 800735,1304 Jefferson Pk Ave, Charlottesville, VA 22908 USA
[3] Northwell Hlth, Feinstein Inst Med Res, Ctr Biomed Sci, 350 Community Dr, Manhasset, NY 11030 USA
[4] Northwell Hlth, Feinstein Inst Med Res, Ctr Bioelect Med, 350 Community Dr, Manhasset, NY 11030 USA
关键词
VAGUS NERVE-STIMULATION; ISCHEMIA-REPERFUSION INJURY; SYSTEMIC INFLAMMATORY RESPONSE; ANGIOTENSIN-II HYPERTENSION; CELL-CYCLE ARREST; RENAL DENERVATION; BLOOD-PRESSURE; MEDIATES PROTECTION; CYTOKINE PRODUCTION; CLINICAL-TRIALS;
D O I
10.1038/nrneph.2017.132
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Neural pathways regulate immunity and inflammation via the inflammatory reflex and specific molecular targets can be modulated by stimulating neurons. Neuroimmunomodulation by nonpharmacological methods is emerging as a novel therapeutic strategy for inflammatory diseases, including kidney diseases and hypertension. Electrical stimulation of vagus neurons or treatment with pulsed ultrasound activates the cholinergic anti-inflammatory pathway (CAP) and protects mice from acute kidney injury (AKI). Direct innervation of the kidney, by afferent and efferent neurons, might have a role in modulating and responding to inflammation in various diseases, either locally or by providing feedback to regions of the central nervous system that are important in the inflammatory reflex pathway. Increased sympathetic drive to the kidney has a role in the pathogenesis of hypertension, and selective modulation of neuroimmune interactions in the kidney could potentially be more effective for lowering blood pressure and treating inflammatory kidney diseases than renal denervation. Use of optogenetic tools for selective stimulation of specific neurons has enabled the identification of neural circuits in the brain that modulate kidney function via activation of the CAP. In this Review we discuss evidence for a role of neural circuits in the control of renal inflammation as well as the therapeutic potential of targeting these circuits in the settings of AKI, kidney fibrosis and hypertension.
引用
收藏
页码:669 / 680
页数:12
相关论文
共 50 条
  • [21] Targeting of Peripheral Innate Immunity by Nasal Proteosome-Based Vaccine To Treat Alzheimer's Disease
    Clalic, Ron
    Butovsky, Oleg
    Larocque, Daniel
    Burt, David
    Pilorget, Anthony
    Baldridge, Jory
    Brichard, Vincent
    Palmantier, Remi
    Weiner, Howard
    NEUROLOGY, 2013, 80
  • [22] Modeling neural control of locomotion: Integration of reflex circuits with CPG
    Rybak, IA
    Ivashko, DG
    Prilutsky, BI
    Lewis, MA
    Chapin, JK
    ARTIFICIAL NEURAL NETWORKS - ICANN 2002, 2002, 2415 : 99 - 104
  • [23] Immunity, microbiota and kidney disease
    Felix Knauf
    J. Richard Brewer
    Richard A. Flavell
    Nature Reviews Nephrology, 2019, 15 : 263 - 274
  • [24] Immunity, microbiota and kidney disease
    Knauf, Felix
    Brewer, J. Richard
    Flavell, Richard A.
    NATURE REVIEWS NEPHROLOGY, 2019, 15 (05) : 263 - 274
  • [25] Immunity and chronic kidney disease
    Tamadon, Mohammad Reza
    IMMUNOPATHOLOGIA PERSA, 2016, 2 (02):
  • [26] To Treat or Not To Treat Renal Anemia of Chronic Kidney Disease Patients?
    Tsubakihara, Yoshiharu
    THERAPEUTIC APHERESIS AND DIALYSIS, 2010, 14 (03) : 235 - 239
  • [27] Strategies for targeting primate neural circuits with viral vectors
    El-Shamayleh, Yasmine
    Ni, Amy M.
    Horwitz, Gregory D.
    JOURNAL OF NEUROPHYSIOLOGY, 2016, 116 (01) : 122 - 134
  • [28] Targeting the Gut Microbiome to Treat Cardiometabolic Disease
    Theofilis, Panagiotis
    Vlachakis, Panayotis K.
    Oikonomou, Evangelos
    Tsioufis, Konstantinos
    Tousoulis, Dimitris
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (02) : 25 - 34
  • [29] Targeting Neuroinflammation to Treat Alzheimer’s Disease
    A. Ardura-Fabregat
    E. W. G. M. Boddeke
    A. Boza-Serrano
    S. Brioschi
    S. Castro-Gomez
    K. Ceyzériat
    C. Dansokho
    T. Dierkes
    G. Gelders
    Michael T. Heneka
    L. Hoeijmakers
    A. Hoffmann
    L. Iaccarino
    S. Jahnert
    K. Kuhbandner
    G. Landreth
    N. Lonnemann
    P. A. Löschmann
    R. M. McManus
    A. Paulus
    K. Reemst
    J. M. Sanchez-Caro
    A. Tiberi
    A. Van der Perren
    A. Vautheny
    C. Venegas
    A. Webers
    P. Weydt
    T. S. Wijasa
    X. Xiang
    Y. Yang
    CNS Drugs, 2017, 31 : 1057 - 1082
  • [30] Targeting Neuroinflammation to Treat Alzheimer's Disease
    Ardura-Fabregat, A.
    Boddeke, E. W. G. M.
    Boza-Serrano, A.
    Brioschi, S.
    Castro-Gomez, S.
    Ceyzeriat, K.
    Dansokho, C.
    Dierkes, T.
    Gelders, G.
    Heneka, Michael T.
    Hoeijmakers, L.
    Hoffmann, A.
    Iaccarino, L.
    Jahnert, S.
    Kuhbandner, K.
    Landreth, G.
    Lonnemann, N.
    Loeschmann, P. A.
    McManus, R. M.
    Paulus, A.
    Reemst, K.
    Sanchez-Caro, J. M.
    Tiberi, A.
    Van der Perren, A.
    Vautheny, A.
    Venegas, C.
    Webers, A.
    Weydt, P.
    Wijasa, T. S.
    Xiang, X.
    Yang, Y.
    CNS DRUGS, 2017, 31 (12) : 1057 - 1082